Marianne Svärd

CMC sub-team lead

Roles in PharmNovo: CMC sub-team lead

Born: 1954

Education: MSc (Chemical engineering); PhD (Physical Chemistry)

Other current appointments: None

Work experience: Independent consultant for 20 years with extensive experience of CMC documentation for CTA and IND applications. The work experience includes development/manufacturing of drug substance and drug product for phase I to phase III clinical trials. Prior to working as an independent consultant Marianne was for instance working at Astra Zeneca in Lund Sweden and Ferring in Malmö Sweden with responsibility for development of new formulations as well as the manufacturing of products approved on the market.

Member of:

Operational team

Latest news

View all

New publication in The Journal of Headache and Pain

August 28, 2026

New publication in The Journal of Headache and Pain

PN6047 publication in The Journal of Headache and Pain strengthens PN6047 potential in migraine and headache disorders PharmNovo is pleased to announce that new preclinical research on PN6047 has been published in The Journal of Headache and Pain, adding to the growing body of scientific evidence supporting the potential of PN6047 beyond neuropathic pain.

Reports of broader therapeutic potential for PN6047

June 29, 2026

Reports of broader therapeutic potential for PN6047

PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.